News
Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...
19h
Zacks.com on MSNNVO Stock up on Plans to Advance Obesity Candidate AmycretinDetailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...
20h
GlobalData on MSNNovo Nordisk ramps up obesity fight, advances amycretin to Phase IIINovo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...
Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...
Blue Cross Blue Shield of Michigan is engaged in the most consequential reimbursement negotiations with hospitals in its 86-year history. The Detroit insurer, the state’s most dominant with a 63% ...
23hon MSN
Starting on a weight loss medication has helped Joie Armstrong prioritize caring for herself, including finding more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results